{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:58:50Z","timestamp":1790513930460,"version":"4.1.0"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["132013-RSG-18-010-01-CCG"],"award-info":[{"award-number":["132013-RSG-18-010-01-CCG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007114","name":"Ralph W. and Grace M. Showalter Research Trust Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007114","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2019.00809","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T04:36:41Z","timestamp":1574138201000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":57,"title":["Bisphosphonate Treatment Ameliorates Chemotherapy-Induced Bone and Muscle Abnormalities in Young Mice"],"prefix":"10.3389","volume":"10","author":[{"given":"Alyson L.","family":"Essex","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua R.","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda F.","family":"Bonewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian I.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bonetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1080\/13696998.2016.1181640","article-title":"Cachexia among US cancer patients","volume":"19","author":"Arthur","year":"2016","journal-title":"J Med Econ"},{"key":"B2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/jcsm.12402","article-title":"Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review","volume":"10","author":"Anker","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13539-010-0002-6","article-title":"Cachexia as a major underestimated and unmet medical need: facts and numbers","volume":"1","author":"von Haehling","year":"2010","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia","volume":"10","author":"Fearon","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s13539-014-0164-8","article-title":"Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014","volume":"5","author":"von Haehling","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/annonc\/mdp605","article-title":"Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma","volume":"21","author":"Antoun","year":"2010","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/MCO.0b013e3283455d45","article-title":"Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity","volume":"14","author":"Prado","year":"2011","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"43442","DOI":"10.18632\/oncotarget.9779","article-title":"Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1\/2 and p38 MAPKs","volume":"7","author":"Barreto","year":"2016","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","first-page":"7590","DOI":"10.4081\/ejtm.2018.7590","article-title":"Chemotherapy-induced muscle wasting: association with NF-\u03baB and cancer cachexia","volume":"28","author":"Damrauer","year":"2018","journal-title":"Eur J Transl Myol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"E571","DOI":"10.3390\/cancers11040571","article-title":"Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles","volume":"11","author":"Huot","year":"2019","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3389\/fphys.2016.00472","article-title":"Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways","volume":"7","author":"Barreto","year":"2016","journal-title":"Front Physiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"14470","DOI":"10.1038\/s41598-017-15040-1","article-title":"ACVR2B\/Fc counteracts chemotherapy-induced loss of muscle and bone mass","volume":"7","author":"Barreto","year":"2017","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1038\/oncsis.2016.3","article-title":"Understanding cachexia as a cancer metabolism syndrome","volume":"5","author":"Porporato","year":"2016","journal-title":"Oncogenesis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bone.2018.11.002","article-title":"Use it or lose it to age: a review of bone and muscle communication","volume":"120","author":"Bonewald","year":"2019","journal-title":"Bone"},{"key":"B16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bone.2015.02.010","article-title":"Bone and muscle: interactions beyond mechanical","volume":"80","author":"Brotto","year":"2015","journal-title":"Bone"},{"key":"B17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/1872208311206030223","article-title":"Prostaglandin E2: from clinical applications to its potential role in bone- muscle crosstalk and myogenic differentiation","volume":"6","author":"Mo","year":"2012","journal-title":"Recent Pat Biotechnol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1172\/JCI125915","article-title":"RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass","volume":"129","author":"Bonnet","year":"2019","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/nm.3961","article-title":"Excess TGF-beta mediates muscle weakness associated with bone metastases in mice","volume":"21","author":"Waning","year":"2015","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11914-007-0027-8","article-title":"Cancer-associated bone disease","volume":"5","author":"Brown","year":"2007","journal-title":"Curr Osteoporos Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e00075","DOI":"10.1002\/j.2617-1619.2019.tb00011.x","article-title":"Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia","volume":"2","author":"Hain","year":"2019","journal-title":"JCSM Rapid Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/2040622310374783","article-title":"Bisphosphonates for the treatment of osteoporosis: insights for clinicians","volume":"1","author":"Lewiecki","year":"2010","journal-title":"Ther Adv Chronic Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.addr.2015.10.005","article-title":"Targeted delivery to bone and mineral deposits using bisphosphonate ligands","volume":"99","author":"Cole","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.5535\/arm.2019.43.3.314","article-title":"Single dose therapy of zoledronic acid for the treatment of transient osteoporosis of hip","volume":"43","author":"Agarwala","year":"2019","journal-title":"Ann Rehabil Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"CD003474-CD","DOI":"10.1002\/14651858.CD003474.pub4","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O'Carrigan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","article-title":"Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody","volume":"76","author":"von Moos","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a cancer care ontario and American society of clinical oncology clinical practice guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"w14440","DOI":"10.4414\/smw.2017.14440","article-title":"Bone targeted therapies in advanced breast cancer","volume":"147","author":"Biskup","year":"2017","journal-title":"Swiss Med Wkly"},{"key":"B30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12894-018-0393-9","article-title":"Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion","volume":"18","author":"Body","year":"2018","journal-title":"BMC Urol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/14656566.2019.1574754","article-title":"Zoledronic acid for the treatment of prostate cancer","volume":"20","author":"Finianos","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"B33","doi-asserted-by":"publisher","first-page":"CD006250-CD","DOI":"10.1002\/14651858.CD006250.pub2","article-title":"Bisphosphonates for advanced prostate cancer","volume":"12","author":"Macherey","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.nmd.2015.09.015","article-title":"Positive effects of bisphosphonates on bone and muscle in a mouse model of Duchenne muscular dystrophy","volume":"26","author":"Yoon","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/jbmr.2162","article-title":"Pamidronate attenuates muscle loss after pediatric burn injury","volume":"29","author":"Borsheim","year":"2014","journal-title":"J Bone Miner Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fendo.2019.00543","article-title":"Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients","volume":"10","author":"Pin","year":"2019","journal-title":"Front Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/jcsm.12023","article-title":"Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved","volume":"6","author":"Chen","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B38","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jcsm.12311","article-title":"Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia","volume":"9","author":"Pin","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B39","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/bonekey.2015.101","article-title":"Assessment of muscle mass and strength in mice","volume":"4","author":"Bonetto","year":"2015","journal-title":"Bonekey Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"7778","DOI":"10.1096\/fj.201802799R","article-title":"PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia","volume":"33","author":"Pin","year":"2019","journal-title":"FASEB J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bone.2019.04.012","article-title":"Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice","volume":"124","author":"Davis","year":"2019","journal-title":"Bone"},{"key":"B42","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"B43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1096\/fj.03-0610com","article-title":"Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression","volume":"18","author":"Lecker","year":"2004","journal-title":"FASEB J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1634\/theoncologist.5-5-353","article-title":"Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition","volume":"5","author":"Curt","year":"2000","journal-title":"Oncologist"},{"key":"B45","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/BF00364968","article-title":"Assessment of fatigue in cancer and non-cancer patients and in healthy individuals","volume":"1","author":"Glaus","year":"1993","journal-title":"Support Care Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S0140-6736(03)14186-4","article-title":"Assessment and management of cancer-related fatigue in adults","volume":"362","author":"Ahlberg","year":"2003","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1002\/cncr.11742","article-title":"Cancer-related fatigue: evolving concepts in evaluation and treatment","volume":"98","author":"Stasi","year":"2003","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/jcsm.12199","article-title":"Muscle mass as a target to reduce fatigue in patients with advanced cancer","volume":"8","author":"Neefjes","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/jncimonographs\/djg014","article-title":"National institutes of health state-of-the-science conference statement: symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002","volume":"95","author":"Patrick","year":"2004","journal-title":"J Natl Cancer Inst Monogr"},{"key":"B50","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1164\/ajrccm\/142.2.474","article-title":"NHLBI Workshop summary. Respiratory muscle fatigue. Report of the Respiratory Muscle Fatigue Workshop Group","volume":"142","author":"Aubier","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1634\/theoncologist.11-10-1121","article-title":"Bone loss and fracture risk associated with cancer therapy","volume":"11","author":"Guise","year":"2006","journal-title":"Oncologist"},{"key":"B52","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0167-5273(02)00235-8","article-title":"Cancer cachexia","volume":"85","author":"Fearon","year":"2002","journal-title":"Int J Cardiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1200\/JCO.2001.19.13.3226","article-title":"Late medical complications and fatigue in Hodgkin's disease survivors","volume":"19","author":"Knobel","year":"2001","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1188\/09.ONF.194-202","article-title":"Fatigue and physical activity in older patients with cancer: a six-month follow-up study","volume":"36","author":"Luctkar-Flude","year":"2009","journal-title":"Oncol Nurs Forum"},{"key":"B55","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s11136-007-9215-3","article-title":"Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL study report","volume":"16","author":"Meeske","year":"2007","journal-title":"Qual Life Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1002\/cncr.26226","article-title":"Prolonged impact of chemotherapy on fatigue in breast cancer survivors: a longitudinal comparison with radiotherapy-treated breast cancer survivors and noncancer controls","volume":"118","author":"Goedendorp","year":"2012","journal-title":"Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1477-7525-7-102","article-title":"Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008","volume":"7","author":"Montazeri","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/cncr.22993","article-title":"Fatigue after treatment for early stage breast cancer: a controlled comparison","volume":"110","author":"Jacobsen","year":"2007","journal-title":"Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jpainsymman.2009.06.011","article-title":"Fatigue in gynecological cancer patients during and after anticancer treatment","volume":"39","author":"Prue","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"B60","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/bonekey.2015.59","article-title":"Cancer-associated muscle weakness: What's bone got to do with it?","volume":"4","author":"Waning","year":"2015","journal-title":"Bonekey Rep"},{"key":"B61","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1056\/NEJM198308043090509","article-title":"Glucocorticoid-induced osteoporosis","volume":"309","author":"Baylink","year":"1983","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2106\/00004623-197153050-00002","article-title":"Corticosteroid-induced avascular necrosis. A clinical study of seventy-seven patients","volume":"53","author":"Fisher","year":"1971","journal-title":"J Bone Joint Surg Am"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1002\/cncr.23437","article-title":"Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma","volume":"112","author":"Kubo","year":"2008","journal-title":"Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/jbmr.2415","article-title":"Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss","volume":"30","author":"Quach","year":"2015","journal-title":"J Bone Miner Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1002\/jcp.23034","article-title":"The role of osteocyte apoptosis in cancer chemotherapy-induced bone loss","volume":"227","author":"Shandala","year":"2012","journal-title":"J Cell Physiol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1749-6632.2002.tb04204.x","article-title":"Mechanisms of glucocorticoid action in bone","volume":"966","author":"Canalis","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1093\/annonc\/mdx360","article-title":"Long-term toxicity of cisplatin in germ-cell tumor survivors","volume":"28","author":"Chovanec","year":"2017","journal-title":"Ann Oncol"},{"key":"B68","first-page":"78","article-title":"Late endocrine effects of cancer and cancer therapies in survivors of childhood malignancies","volume":"41","author":"Marques","year":"2016","journal-title":"Minerva Endocrinol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1210\/jc.2014-1722","article-title":"Changes in bone mineral density in newly diagnosed testicular cancer patients after anticancer treatment","volume":"99","author":"Willemse","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B71","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s10549-010-0899-7","article-title":"Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?","volume":"123","author":"Cameron","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"B72","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1113\/jphysiol.2011.212845","article-title":"Muscle sparing in muscle RING finger 1 null mice: response to synthetic glucocorticoids","volume":"589","author":"Baehr","year":"2011","journal-title":"J Physiol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nature10763","article-title":"The contribution of bone to whole-organism physiology","volume":"481","author":"Karsenty","year":"2012","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1210\/er.2012-1026","article-title":"The osteocyte: an endocrine cell \u2026 and more","volume":"34","author":"Dallas","year":"2013","journal-title":"Endocr Rev"},{"key":"B75","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J"},{"key":"B76","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3389\/fphys.2016.00679","article-title":"Differential bone loss in mouse models of colon cancer cachexia","volume":"7","author":"Bonetto","year":"2017","journal-title":"Front Physiol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/nm.3988","article-title":"A TGF-beta pathway associated with cancer cachexia","volume":"21","author":"Guttridge","year":"2015","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11914-017-0344-5","article-title":"The role of TGF\u03b2 in bone-muscle crosstalk","volume":"15","author":"Regan","year":"2017","journal-title":"Curr Osteoporos Rep"},{"key":"B79","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/jbm.a.31085","article-title":"Quantification of various growth factors in different demineralized bone matrix preparations","volume":"81","author":"Wildemann","year":"2007","journal-title":"J Biomed Mater Res A"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.bbrc.2009.12.123","article-title":"Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia","volume":"391","author":"Benny Klimek","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/ng.2772","article-title":"BMP signaling controls muscle mass","volume":"45","author":"Sartori","year":"2013","journal-title":"Nat Genet"},{"key":"B82","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bone.2014.03.008","article-title":"Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women","volume":"64","author":"Levinger","year":"2014","journal-title":"Bone"},{"key":"B83","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/206489a0","article-title":"Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling","volume":"206","author":"Hattner","year":"1965","journal-title":"Nature"},{"key":"B84","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12893-017-0299-6","article-title":"Association of pelvic fracture patterns, pelvic binder use and arterial angio-embolization with transfusion requirements and mortality rates; a 7-year retrospective cohort study","volume":"17","author":"Agri","year":"2017","journal-title":"BMC Surg"},{"key":"B85","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/B978-0-12-813259-3.00016-6","article-title":"Chapter: Bone and Muscle","volume-title":"Basic and Applied Bone Biology","author":"Bonetto","year":"2019"},{"key":"B86","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.bone.2015.02.009","article-title":"Wnt signaling in bone and muscle","volume":"80","author":"Rudnicki","year":"2015","journal-title":"Bone"},{"key":"B87","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1084\/jem.188.5.997","article-title":"TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts","volume":"188","author":"Fuller","year":"1998","journal-title":"J Exp Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"C663","DOI":"10.1152\/ajpcell.00285.2015","article-title":"Muscle RANK is a key regulator of Ca2+ storage, SERCA activity, and function of fast-twitch skeletal muscles","volume":"310","author":"Dufresne","year":"2016","journal-title":"Am J Physiol Cell Physiol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40478-018-0533-1","article-title":"Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy","volume":"6","author":"Dufresne","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.molmet.2016.07.002","article-title":"Osteocalcin is necessary and sufficient to maintain muscle mass in older mice","volume":"5","author":"Mera","year":"2016","journal-title":"Mol Metab"},{"key":"B91","doi-asserted-by":"publisher","first-page":"E863","DOI":"10.1152\/ajpendo.00596.2012","article-title":"FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy","volume":"304","author":"Touchberry","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B92","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1073\/pnas.1705420114","article-title":"Prostaglandin E2 is essential for efficacious skeletal muscle stem-cell function, augmenting regeneration and strength","volume":"114","author":"Ho","year":"2017","journal-title":"Proc Nat Acad Sci USA"},{"key":"B93","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/bonekey.2013.215","article-title":"Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit","volume":"3","author":"Sims","year":"2014","journal-title":"Bonekey Rep"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1359\/jbmr.080706","article-title":"Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling","volume":"23","author":"Walker","year":"2008","journal-title":"J Bone Miner Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1080\/08977190701781289","article-title":"Cardioprotective role of cardiotrophin-1 gene transfer in a murine model of myocardial infarction","volume":"25","author":"Ruixing","year":"2007","journal-title":"Growth Factors"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1167\/iovs.09-4414","article-title":"Insulin-like growth factor-1 and cardiotrophin 1 increase strength and mass of extraocular muscle in juvenile chicken","volume":"51","author":"Li","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/cr.2017.87","article-title":"Cardiotrophin 1 stimulates beneficial myogenic and vascular remodeling of the heart","volume":"27","author":"Abdul-Ghani","year":"2017","journal-title":"Cell Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.phrs.2017.08.013","article-title":"Sphingosine 1-phosphate (S1P) signalling: Role in bone biology and potential therapeutic target for bone repair","author":"Sartawi","year":"2017","journal-title":"Pharmacol Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e108662","DOI":"10.1371\/journal.pone.0108662","article-title":"Mesenchymal stromal cell secreted sphingosine 1-phosphate (S1P) exerts a stimulatory effect on skeletal myoblast proliferation","volume":"9","author":"Sassoli","year":"2014","journal-title":"PLoS ONE"},{"key":"B100","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ydbio.2016.06.024","article-title":"Sphingosine 1-phosphate receptor-1 in cardiomyocytes is required for normal cardiac development","volume":"418","author":"Clay","year":"2016","journal-title":"Dev Biol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"L609","DOI":"10.1152\/ajplung.00554.2017","article-title":"Sphingosine-1-phosphate induces airway smooth muscle cell proliferation, migration, and contraction by modulating Hippo signaling effector YAP","volume":"315","author":"Liu","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"B103","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bone.2015.02.018","article-title":"The skeletal muscle cross sectional area in long-term bisphosphonate users is smaller than that of bone mineral density-matched controls with increased serum pentosidine concentrations","volume":"75","author":"Uchiyama","year":"2015","journal-title":"Bone"},{"key":"B104","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"Risks and benefits of bisphosphonate therapies","volume":"117","author":"Reyes","year":"2016","journal-title":"J Cell Biochem"},{"key":"B105","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1002\/hed.25717","article-title":"Weekly cisplatin chemotherapy dosing vs. triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinoma","volume":"41","author":"Morse","year":"2019","journal-title":"Head Neck"},{"key":"B107","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs. 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00809\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T01:14:58Z","timestamp":1665018898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00809\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":107,"alternative-id":["10.3389\/fendo.2019.00809"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2019.00809","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,19]]},"article-number":"809"}}